Neuroscience 2001 Abstract
| Presentation Number: | 688.7 |
|---|---|
| Abstract Title: | Mapping dopaminergic function in normal and MPTP treated monkeys with pharmacologic MRI and PET. |
| Authors: |
Jenkins, B. G.*1
; Chen, Y. I.1
; Sanchez Pernaute, R.3
; Owen, C.1
; Flaherty, A. W.2
; Isacson, O.3
; Brownell, A. L.1
1Radiology, Massachusetts General Hospital, Charlestown, MA 2Neurology, Massachusetts General Hospital, Charlestown, MA 3Udall Parkinson's Disease Research Center of Excellence, McLean Hospital, Belmont, MA |
| Primary Theme and Topics |
Neurological and Psychiatric Conditions - Neurodegenerative Disorders -- Parkinsons Disease: Other |
| Secondary Theme and Topics | Synaptic Transmission and Excitability<br />- Neurotransmitters<br />-- Catecholamines |
| Session: |
688. Neurodegenerative disorders: Parkinson's disease--animal models Slide |
| Presentation Time: | Wednesday, November 14, 2001 9:30 AM-9:45 AM |
| Location: | Room 29D |
| Keywords: | AMPHETAMINE, PARKINSON'S DISEASE, DOPAMINE, METABOLISM |
Introduction In this work we investigate how the hemodynamic changes evoked by D-amphetamine in normal and MPTP treated monkeys can be mapped using pharmacologic MRI (phMRI) and PET to validate the degree of dopaminergic denervation after MPTP treatment.
Methods
Macaca Fascicularis: 6 normal control monkeys and 3 MPTP treated monkeys (2 with minor and 1 with severe PD symptoms).
MRI phMRI images of cerebral blood volume changes were collected on a Siemen's 3T allegra system for 60-120 minutes (50sec/image set). 1.5-2.5mg/kg amphetamine was used to probe dopaminergic function.
PET 11C-CFT was used to assess the binding potential of the dopamine transporter protein (DAT) in the striatum.
Results Administration of amphetamine to control monkeys produced strong phMRI activation in caudate, putamen, accumbens, thalamus, and substantia nigra (increase in CBV between 10-35%). There was much less cortical activation compared to our prior rat phMRI studies. For the MPTP-treated monkeys with minor symptoms and moderate DAT loss, activation in motor cortex was observed in addition to the areas above. The severely Parkinsonian monkey showed little change in CBV anywhere after amphetamine administration.
PET with 11C-CFT validated 30% decrease in DAT binding in the monkeys with mild, and 67% decrease in the severely Parkinsonian one.
Conclusions We demonstrate here phMRI can be used to investigate dopaminergic function and neuronal recruitment in Parkinson's disease.
Methods
Macaca Fascicularis: 6 normal control monkeys and 3 MPTP treated monkeys (2 with minor and 1 with severe PD symptoms).
MRI phMRI images of cerebral blood volume changes were collected on a Siemen's 3T allegra system for 60-120 minutes (50sec/image set). 1.5-2.5mg/kg amphetamine was used to probe dopaminergic function.
PET 11C-CFT was used to assess the binding potential of the dopamine transporter protein (DAT) in the striatum.
Results Administration of amphetamine to control monkeys produced strong phMRI activation in caudate, putamen, accumbens, thalamus, and substantia nigra (increase in CBV between 10-35%). There was much less cortical activation compared to our prior rat phMRI studies. For the MPTP-treated monkeys with minor symptoms and moderate DAT loss, activation in motor cortex was observed in addition to the areas above. The severely Parkinsonian monkey showed little change in CBV anywhere after amphetamine administration.
PET with 11C-CFT validated 30% decrease in DAT binding in the monkeys with mild, and 67% decrease in the severely Parkinsonian one.
Conclusions We demonstrate here phMRI can be used to investigate dopaminergic function and neuronal recruitment in Parkinson's disease.
Supported by NIHP50NS39793 and DAMD-17-98-1-8618
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2001 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2001. Online.
Copyright © 2001-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
